Summary of Study ST001202
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000809. The data can be accessed directly via it's Project DOI: 10.21228/M83X38 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST001202 |
Study Title | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites |
Study Summary | Red blood cells (RBCs) infected with ring stage P. falciparum parasites (3D7 strain) at 10% parasitaemia and 2% haematocrit were treated with OZ277 (1 uM), OZ439 (1 uM), DHA (300 nM) or vehicle (0.03% DMSO). This was a 5-timepoint study, with samples taken 0, 1.5, 3, 6 and 9 h after drug or vehicle addition. Samples treated with vehicle acted as the untreated control. Samples from drug treated uninfected RBCs were also taken to ensure the observed drug effects were parasite specific. |
Institute | Monash University |
Last Name | Giannangelo |
First Name | Carlo |
Address | 381 Royal Parade, Parkville, Victoria, 3052, Australia |
carlo.giannangelo@monash.edu | |
Phone | 99039282 |
Submit Date | 2019-06-24 |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Thermo) |
Analysis Type Detail | LC-MS |
Release Date | 2019-07-17 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR001284 |
Treatment Summary: | Ring stage P. falciparum infected RBCs (10% parasitaemia and 2% Hct) were treated with OZ277 (1 uM), OZ439 (1 uM), DHA (300 nM) or an equivalent volume of DMSO (0.03%). DHA-treated cultures were incubated with drug for 0, 1.5, 3 and 6 h. OZ277- and OZ439-treated cultures were incubated with drug for 0, 3, 6 and 9 h. During the drug incubation period parasites were at 37°C under a gas atmosphere of 94% N2, 5% CO2 and 1% O2. |
Treatment Compound: | OZ277 (arterolane), OZ439 (artefenomel) and dihydroartemisinin (DHA) |
Treatment Vehicle: | DMSO |
Cell Media: | Complete RPMI medium (10.4 g/L) containing HEPES (5.94 g/L), hypoxanthine (50 mg/L), sodium bicarbonate (2.1 g/L) and Albumax II (5 g/L). |
Cell Media Lastchanged: | Immediately prior to initiation of drug incubation |